This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (36)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Osteoporosis  • Aging/ Geriatrics  • Alert me on articles by topic

Strategies for Preventing Fractures in the Elderly

Mark P. Ettinger, MD

Arch Intern Med. 2003;163:2237-2246.

As the older population increases, the incidence of osteoporotic fractures is expected to dramatically rise during the next few decades. Older patients are much more susceptible to fracture at any given bone mineral density (BMD) than are younger patients because of various factors, including the quality of aging bone, which involves more than BMD. Suppression of increased bone turnover by antiresorptive therapies, even with only small changes in BMD, can reduce fracture risk, especially in the lumbar spine. Bisphosphonate treatment can significantly reduce vertebral and nonvertebral fractures, including hip fractures, even in the very elderly. Prospective analyses show that risedronate therapy consistently and significantly reduces the risk of new morphometric vertebral fractures after 1 year in postmenopausal women. Post hoc analyses report significant reductions in the risk of 1 new clinical vertebral fracture after 6 months of risedronate therapy and after 1 year of alendronate therapy. Oral raloxifene therapy and salmon calcitonin nasal spray therapy have been shown to reduce the risk of vertebral fracture after 3 and 5 years, respectively, and post hoc data show a significant reduction in clinical vertebral fracture risk at 1 year with raloxifene use. However, neither raloxifene therapy nor calcitonin therapy reduce the risk of nonvertebral and hip fractures at currently approved doses. Bisphosphonates have been shown to be safe and efficacious with 7 years' risedronate sodium and 10 years' alendronate sodium data published, and bisphosphonates reduce bone turnover and increase BMD to a greater degree than raloxifene and calcitonin, which may partly account for their nonvertebral and hip fracture reduction effect. Therefore, bisphosphonate therapy with risedronate or alendronate should be considered in patients with low BMD at the hip and in older patients with osteoporosis and osteopenia, particularly those with an existing fracture.

From the Regional Osteoporosis Center of South Florida and Radiant Research Stuart Florida, Stuart. Dr Ettinger has received clinical research grant support from and/or has been a consultant for Procter & Gamble Pharmaceuticals, Eli Lilly & Co, Merck & Co, Inc, Novartis AG, and Wyeth Ayerst.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hip Fracture Risk Among Community-Dwelling Elderly People in the United States: A Prospective Study of Physical, Cognitive, and Socioeconomic Indicators
Wilson et al.
Am. J. Public Health 2006;96:1210-1218.
ABSTRACT | FULL TEXT  

Folate, But Not Homocysteine, Predicts the Risk of Fracture in Elderly Persons
Ravaglia et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2005;60:1458-1462.
ABSTRACT | FULL TEXT  

Sustained effect of short-term calcium supplementation on bone mass in adolescent girls with low calcium intake
Dodiuk-Gad et al.
Am. J. Clin. Nutr. 2005;81:168-174.
ABSTRACT | FULL TEXT